Statement by Chip Davis, President and CEO, GPhA, Regarding the European Union Proposal for Regulatory Cooperation on Generic Medicines
Contact: Steve Arnoff 202.249.7113
WASHINGTON, DC (Feb. 11, 2016) —
“GPHA is very pleased that the European Commission is taking steps to advance pharmaceutical regulatory cooperation between Europe and the United States.
In a new technical paper, the European Commission outlines areas for greater efficiencies in the development of complex generic products for Europe and the United States. GPhA, in collaboration with the EGA, commends the European Commission’s efforts to advance this initiative under TTIP in order to allow safe, effective and affordable medicines to reach patients sooner by eliminating duplicative regulatory obstacles.
The association looks forward to continued progress on this initiative in order to foster greater competition and promote pharmaceutical trade between both markets.”
The European Commission technical paper is available here.
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 88 percent of the prescriptions dispensed in the U.S. but consume just 28 percent of the total drug spending. Additional information is available at gphaonline.org. Follow us on twitter: @gpha.